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ABSTRACT
Functional renal magnetic resonance imaging (MRI) has seen a
number of recent advances, and techniques are now available
that can generate quantitative imaging biomarkers with the
potential to improve the management of kidney disease. Such
biomarkers are sensitive to changes in renal blood ﬂow, tissue
perfusion, oxygenation and microstructure (including inﬂam-
mation and ﬁbrosis), processes that are important in a range of
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renal diseases including chronic kidney disease. However, several
challenges remain to move these techniques towards clinical
adoption, from technical validation through biological and
clinical validation, to demonstration of cost-effectiveness and
regulatory qualiﬁcation. To address these challenges, the
European Cooperation in Science and Technology Action
PARENCHIMAwas initiated in early 2017. PARENCHIMA is a
multidisciplinary pan-European network with an overarching
aim of eliminating the main barriers to the broader evaluation,
commercial exploitation and clinical use of renal MRI bio-
markers. This position paper lays out PARENCHIMA’s vision
on key clinical questions that MRI must address to becomemore
widely used in patients with kidney disease, ﬁrst within research
settings and ultimately in clinical practice. We then present a se-
ries of practical recommendations to accelerate the study and
translation of these techniques.
Keywords: biomarker, chronic kidney disease, ﬁbrosis, inﬂam-
mation, MRI
INTRODUCTION
The global burden of kidney disease is significant, as >10% of
the world’s adult population has chronic kidney disease
(CKD) and in developed countries alone >2million people
sustain acute kidney injury (AKI) annually [1, 2]. Moreover,
the incidences of both CKD and AKI are rising. Progression
to end-stage kidney disease (ESKD) and cardiovascular com-
plications impact significantly on patients’ outcomes, their
quality of life and health care resource utilization. In the UK,
1.3% of National Health Service (NHS) spending
(£1.45 billion per annum) has been attributed to CKD [3].
Landmark publications have consistently reinforced these
messages and delineated the key areas in which progress is
needed, specifically highlighting the need for better methods
to diagnose kidney diseases [1, 4].
Current methods to assess CKD (e.g. serum creatinine, albu-
minuria and ultrasound) are insensitive to early kidney damage,
do not usually provide insight into the aetiology of underlying
kidney disease and do not reliably allow individual patient strat-
ification in terms of prognosis or therapy decisions. Kidney bi-
opsy is the only current method to assess renal microstructure,
but it has several disadvantages, including its invasive nature
and susceptibility to sampling bias. The clinical need for more
specific diagnostic and prognostic tools is seen across the pa-
tient pathway and improved biomarkers that can determine the
aetiology of kidney disease or characterize the dominant patho-
physiological process in individual patients are urgently
required.
Recent developments in functional and quantitative renal
magnetic resonance imaging (MRI) techniques show great po-
tential to address these challenges. There are now several tech-
niques to generate MRI biomarkers, which can measure
biophysical tissue properties that have been linked to fibrosis,
inflammation, tissue oedema, perfusion, filtration and tissue ox-
ygenation [5–15]. The most commonly encountered functional
MRI techniques are summarized in Table 1. In contrast to con-
ventional MRI, which is geared towards visual identification of
gross anatomical changes, these new methods provide a
means to characterize subtle tissue alterations caused by a
range of kidney diseases. As such, MRI biomarkers may be
able to pick up early signs of disease progression that have not
yet led to a discernible effect on markers in blood and urine.
In addition, MRI biomarkers are unique among diagnostic
tools in that they characterize the entire kidney in high-spatial
detail, are able to detect cortico-medullary and left-right
changes separately, do not use ionizing radiation and can as-
sess the degree of functional heterogeneity across the kidney.
MRI is the only technique able to study the renal medulla
in vivo, an area that may play an important role in the patho-
genesis of CKD and AKI [32, 33].
In early 2017, the Cooperation in Science and Technology
(COST) Action PARENCHIMA was formed to increase the
standardization and availability of renal MRI biomarkers and
drive a broader clinical uptake (www.renalmri.org). This posi-
tion paper is the output of expert meetings of PARENCHIMA
Working Group 3 (Bergamo, 13 July 2017; Berlin, 13 October
2017; Utrecht, 23 April 2018) and has two separate aims:
(i) identify the key clinical questions related to CKD where MRI
biomarkers can provide added value and improve patient
outcomes and (ii) propose strategic recommendations for
future clinical research studies involving functional renal MRI.
THE POTENTIAL CLINICAL UTILITY OF MRI
BIOMARKERS
In this section, the possible clinical applications of MRI are
discussed using the biomarker classification scheme proposed
by the Biomarker Working Group of the US Food and
Drug Administration (FDA) and the National Institutes of
Health [34].
Diagnostic biomarkers: diagnosis and classification of
disease
CKD is defined in the Kidney Disease: Improving Global
Outcomes (KDIGO) guidelines as abnormalities of kidney
structure or function present for >3months that have implica-
tions for health. The criteria include a reduced glomerular filtra-
tion rate (GFR), the presence of albuminuria or abnormalities
of kidney structure [35]. Currently the aetiology of CKD
remains unknown or at least uncertain in as many as 50% of
patients [36]. In addition, early diagnosis of progressive condi-
tions before the onset of reduced GFR or albuminuria may be
of clinical benefit but is not possible at present [37]. CKD pro-
gression and maladaptive repair after AKI are characterized by
a similar combination of mechanisms, including tissue injury,
inflammation, haemodynamic alterations (glomerular capillary
hyperfiltration and hypertension), vascular rarefaction, hypoxia
and fibrosis [38, 39]. Probably the best predictor of declining re-
nal function identified in clinical studies is interstitial fibrosis
[38, 39]. While fibrosis is regarded as the final common path-
way, CKD progression is a dynamic process in which these
multiple mechanisms occur in a mutually stimulating fashion.
CKD is therefore a heterogeneous syndrome with cause and
outcomes varying significantly between individuals.
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Table 1. Description of the most common MRI biomarkers currently available for assessment of kidney disease
MRI technique Description of MRI technique Pathophysiological processes in-
formed by MRI biomarker
Biomarker measured Units of measurement
Volumetry [16, 17–19] Gold standard technique.
Volumes measured from T1-
and/or T2-weighted structural
images.
Kidney length and volume and
their change over time are key mea-
sure in patients with ADPKD but
may also be important in CKD pro-
gression, primary and secondary
hyperﬁltration in diabetic nephrop-
athy, renal transplants, renal artery
stenosis, vesicoureteric reﬂux.
Cortical thickness may be more
variable within a given kidney, lim-
iting reproducibility.
TKV
Height-adjusted TKV
Cortical volume
Total cyst volume in
ADPKD
Cortical thickness
mL
mL/m
mL
mL
mm
Phase contrast
MRI [20]
Measures blood ﬂow in renal ar-
teries. Exploits the different prop-
erties of moving versus static
protons in a magnetic ﬁeld. A
moving proton will have a ‘phase
shift’ proportional to its velocity,
allowing calculation of ﬂow.
Increased renal resistance to ﬂow
due to downstream microvascular
obstruction, large-vessel arterial
disease or changes in systemic
haemodynamics.
Renal artery blood
ﬂow (ﬂux)
Renal artery velocity
Renal artery area
mL/s
cm/s
cm2
ASL [14, 21–24] ASL uses magnetically labelled
water protons in blood that act as
a diffusible tracer providing an
internal endogenous contrast, fol-
lowing which labelled images are
subtracted from control images
to generate perfusion maps.
Cortical perfusion, which can be af-
fected by a number of pathophysio-
logical processes in acute and
chronic renal disease.
Tissue blood ﬂow mL/min/100g
Diffusion weighted im-
aging (DWI) [12, 25]
Detects the displacement of water
molecules within the architecture
of tissues and quantiﬁes this as
the ADC. ADC may be affected
by tubular ﬂow and capillary per-
fusion, so true diffusion (D) can
be measured using the IntraVoxel
Incoherent Motion (IVIM)
model, alongside pseudo-diffu-
sion (tubular/vascular ﬂow, D*)
and ﬂowing fraction (F).
Any changes in the renal micro-
structure, especially in the intersti-
tium, for instance, renal ﬁbrosis,
cellular inﬁltration (inﬂammatory
or tumorous) or oedema, changes
in renal perfusion and in water
handling in the tubular
compartment.
ADC
True diffusion (D)
Pseudo-diffusion (D*)
Flowing fraction (F)
mm2/s
mm2/s
mm2/s
%
Diffusion-tensor
imaging (DTI) [12, 26]
Similar to DWI but also assesses
directionality of diffusion
(Brownian motion), which is
quantiﬁed as a percentage of spa-
tially oriented diffusion signal
[fractional anisotropy (FA)].
Allows assessment of the degree
of organization in space of ori-
ented tissues.
Any changes in the microstructure
that lead to a change in the pre-
ferred direction of water diffusion,
for instance, tubular dilatation, tu-
bular obstruction or a loss in the
organization of medullary tubules.
FA
MD (mean diffusivity)
Scale value between 0 and
1, where 0 ¼ isotropic
diffusion (equal in all
directions) and
1 ¼ complete anisotropy
(diffusion in a single axis)
mm2/s
BOLD MRI [13, 27] Indirect assessment of oxygena-
tion. Paramagnetic properties of
deoxygenated haemoglobin act to
shorten the transverse relaxation
time constant (T2*).
Changes in renal oxygenation or
changes in the microstructure of the
capillary bed. Other factors such as
hydration status, dietary sodium and
susceptibility effects also alter T2*.
T2*
R2* (1/ T2*)
ms
s1
T1 mapping [5, 15] Provides a quantitative map over
the whole kidney for T1 values.
T1 is a tissue-speciﬁc time vari-
able that can distinguish different
tissues.
Changes in the molecular environ-
ment, for example, water content,
viscosity, temperature, ﬁbrosis (due
to the association of collagen with
supersaturated hydrogel) and in-
ﬂammation (interstitial oedema,
cellular swelling).
T1
(whole kidney, cortex,
medulla, cortico-
medullary difference)
ms
T2 mapping [15, 28] As with T1 mapping, provides
quantiﬁcation of T2 as a tissue-
speciﬁc time parameter. Changes
with tissue water content.
Changes in the molecular environ-
ment but assumed to be more sen-
sitive to the effects of oedema and/
or inﬂammation. Limited experi-
ence in human kidney disease to
date.
T2
(whole kidney, cortex,
medulla, cortico-
medullary difference)
ms
Continued
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Currently, renal biopsy is the only tool in clinical practice
that allows assessment of renal microstructure, pathology or the
degree of fibrosis. Only a proportion of patients with CKD un-
dergo renal biopsy. This is usually those with greater degrees of
non-diabetic proteinuria and/or progressively declining esti-
mated GFR (eGFR), and is mostly performed in the earlier
stages of CKD. In patients with a renal transplant, biopsy is per-
formed in response to graft dysfunction, although some centres
also perform protocol biopsies to screen for subclinical rejection
or chronic allograft nephropathy. However, renal biopsy has
disadvantages: it is invasive (causing discomfort and risking
complications), it is susceptible to sampling bias (examining
only0.002% of the total glomeruli of one kidney) and it is dif-
ficult to perform repeatedly to assess serial changes. Moreover,
biopsy is problematic in specific patient categories (e.g. patients
on anticoagulation and smaller kidney size), contraindicated in
others (e.g. cystic kidney disease) and is limited in that it does
not routinely sample the medulla, an area uniquely sensitive to
hypoxic injury. Therefore significant challenges remain in cur-
rent clinical practice to characterize the dominant pathophysio-
logical processes in an individual.
There are now a number of techniques within the arma-
mentarium of renal MRI that offer the unique opportunity to
assess the different pathological processes in-vivo, on a whole-
organ basis and without the need for intravenous contrast
agents [40]. Establishing the biological validity of these meas-
ures is an important first step in the biomarker pathway. This
refers to the determination of which biological processes rele-
vant to CKD can be specifically and reliably detected and
quantified by these methods and which are the optimal MRI
measures or combination of measures to do so. To date, how-
ever, very few current studies have thoroughly characterized
the specificity of MRI biomarkers for discrete pathological
processes, creating a situation where individual magnetic
resonance (MR) techniques may be confounded by a number
of clinical, physiological and pathological variables.
Furthermore, the majority of MRI biomarkers have been
assessed in isolation, making it difficult to determine which
are the optimal MRI measures or combinations of measures
for a given biological process. This is important as combina-
tions of MRI biomarkers are likely to be more effective at un-
derstanding and describing specific pathophysiological
processes. Similarly, there may be added value from the inte-
gration of renal MRI measures with circulating or urinary bio-
markers of GFR or tubular injury.
Prognostic biomarkers: predicting disease progression
In addition to the question of whether MRI biomarkers can
identify or measure aspects of biology that are relevant to renal
disease, it is also important to establish whether they are able to
predict important clinical outcomes (clinical validity). Adverse
clinical outcomes include CKD progression, increased mortal-
ity, cardiovascular events and increased risk of AKI. While hard
clinical endpoints such as progression to ESKD are widely ac-
cepted (including by regulatory bodies), the challenge for clini-
cal studies is that prolonged follow-up periods, large sample
sizes or the study of advanced disease stages are often necessary
to adequately test these endpoints. This has led to extensive
Table 1. Continued
MRI technique Description of MRI technique Pathophysiological processes in-
formed by MRI biomarker
Biomarker measured Units of measurement
MR renography [26]
[sometimes referred to
as dynamic contrast
enhanced (DCE) MRI]
Uses gadolinium-based contrast
agents to change the T1 relaxation
time of water in tissues. Allows
measurement of perfusion and
GFR. Concerns exist when using
gadolinium for research in ad-
vanced CKD (hence not dis-
cussed in this paper).
Perfusion and ﬁltration per unit tis-
sue, vascularity and tubular transit
times.
Single kidney GFR
Tissue blood ﬂow
Tubular ﬂow
Filtration fraction
Tubular transit time
Tubular volume
fraction
mL/min
mL/min/100mL
mL/min/100mL
%
min
%
Magnetization transfer
(MT) [29]
A technique that is dependent on
the fraction of large macromole-
cules or immobilized cell mem-
branes in tissue. Also can be used
as an adjunct to MRI angiogra-
phy to suppress background tis-
sue signal.
The fraction of large macromole-
cules or immobilized cell mem-
branes in tissue; in the kidney,
shown to correlate with ﬁbrosis.
MT ratio %
Emerging techniques
[9, 30, 31]
A number of additional func-
tional MRI techniques are also
described, which currently re-
quire a larger amount of technical
validation and are less widely
available than other methods de-
scribed in this table. These in-
clude (but are not limited to)
elastography, hyperpolarization,
and 23-sodium MRI.
Technique dependent Technique dependent Technique dependent
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debate in themedical literature about the definition of surrogate
endpoints of CKD progression [41], a variety of which have
been proposed, including the trajectory of eGFR decline, per-
centage change in eGFR over time, threshold values of eGFR
cut-offs, reductions in albuminuria and combinations of these
[42, 43].
A well-known example of a prognostic MRI biomarker is to-
tal kidney volume (TKV) in autosomal dominant polycystic
kidney disease (ADPKD). TKV is most accurately measured by
MRI and is approved by the FDA as a prognostic enrichment
biomarker to select patients for interventional clinical trials
who are at higher risk for a progressive decline in renal function
[44]. In clinical practice, TKV is now used as a biomarker to
help inform the decision to initiate therapy with tolvaptan [45].
More generally, there remains a clear clinical need to better dif-
ferentiate the large variation that is seen in individual risk of
CKD progression. Illustrating this, in a Norwegian health sur-
vey cohort only 1.2% of a primary care CKD population pro-
gressed to ESKD, in contrast to much higher progression rates
when proteinuria, diabetes or hypertension coexist [46, 47]. In
an attempt to improve the characterization of individual risk of
CKD progression, several prediction models based on clinical
data have been developed, of which the Kidney Failure Risk
Equation (KFRE) is the most widely accepted [48]. The score
has been validated in several international cohorts and repre-
sents the current standard in ESKD risk prediction, despite be-
ing applicable only to CKD Stages 3–5 and over a relatively
short time frame (the subsequent 5 years) [49, 50]. An area of
recent progress in the application of functional MRI to charac-
terize the risk of CKD progression is the use of blood
oxygenation level dependent (BOLD) MRI, which has been
shown to identify patients at risk for ESKD or rapid renal func-
tion decline over the subsequent 3 years [51]. Emerging evi-
dence in diabetic kidney disease has also shown that arterial
spin labelling (ASL) measurement of cortical perfusion may de-
tect early haemodynamic changes [52].
Biomarkers that can predict patients’ risk of subsequent CKD
progression would be valuable on several fronts. This would al-
low for better targeting or intensified treatment of higher-risk
groups. Enrichment of study populations for clinical trials would
also be possible, increasing the proportion of recruited patients
at increased risk of progression, thus improving the efficiency of
the trial and its likelihood of success. Timely preparation for re-
nal replacement therapy (RRT) could be better delivered in those
with progression despite treatment. Conversely, in low-risk
patients, unnecessary interventions could be avoided, benefiting
patients and reducing health care costs.
However, there are some additional considerations that are
relevant to the establishment of clinical utility. It will be impor-
tant to determine whether MRI biomarkers associate with
adverse outcomes and whether they add significant improve-
ments in performance to our current ability to identify patients
at high risk of progression. Furthermore, the high cost of MRI
scans and elaborate image processing is a critical factor in their
ultimate utility and solid health economic evaluation should
therefore be integrated early in the MRI biomarker develop-
ment process.
Predictive biomarkers: patient selection for treatment
A promising area of application for MRI biomarkers is in
targeting treatment choices based on more precise knowledge
of mechanisms of disease and/or the risk of adverse outcomes
in an individual. If MRI is used to enrich the study population
for a clinical trial, a positive outcome for the intervention stud-
ied could lead to translation of the MRI biomarker into clinical
practice as a companion diagnostic to identify patients suitable
for the novel treatment. As examples, the ability to differentiate
between active inflammation and fibrosis in a patient with CKD
secondary to vasculitis or in a renal transplant would inform
therapeutic decisions around the intensity of immunosuppres-
sive therapy, which carries associated risks as well as potential
therapeutic benefits. Renal perfusion and blood flow measured
by ASL and phase contrast MRI may characterize the haemody-
namic and thus potentially reversible consequences of treat-
ments known to affect renal blood flow, such as inhibitors of
the renin–angiotensin system [21]. Also, MR-derived struc-
ture–function relationships may predict those patients with re-
novascular disease most likely to respond to renal artery
stenting [53]. MRI biomarkers could also be used to identify
those patients in whom disease is too advanced to benefit from
specific treatments. Such patients could then be excluded from
clinical trials and in clinical practice avoid unnecessary treat-
ments and their side effects.
Monitoring biomarkers: response to treatment
Renal MRI can also provide an improved way of monitoring
response to therapy. In a small number of centres, this is current
practice in patients with ADPKD treated with tolvaptan. It is
also required in patients with tuberous sclerosis and angiomyo-
lipoma treated with everolimus (NHS England Clinical
Commissioning policy B14X09). In other forms of CKD, the ef-
fectiveness of treatment is currently monitored by eGFR and
proteinuria; the degree of albuminuria reduction after the intro-
duction of renin–angiotensin–aldosterone system blockade
associates with a lower risk of CKD progression in diabetic and
non-diabetic CKD [47, 54–56]. However, methods to provide
improved assessments of response to treatment would certainly
be of value, more so because non-proteinuric rather than pro-
teinuric renal diseases are the leading cause of ESKD [57]. MRI
measures without the need for intravenous contrast agents and
without the risks of ionizing radiation are well suited to serial
application. They can be performed before and after initiation
of treatment and repeated serially over a longer time course to
inform whether a treatment is providing benefit or to determine
whether treatment needs to be changed in case of lack of ade-
quate response. This may allow the monitoring of response to
renoprotective therapy without the need for serial renal biopsies
[58] and would be particularly important for treatments that
are high risk or expensive, so that treatment is continued when
effective but stopped earlier than currently when ineffective.
However, using MRI biomarkers to assess treatment response
will require robust validation of variability of the MRI
measures.
ii8 N.M. Selby et al.
Safety biomarkers: detecting drug toxicity
The same paradigm could be used to monitor for renal
toxicity, for example, in high-risk populations such as those
undergoing specific types of chemotherapy, or to monitor the
nephrotoxic effects of any new drugs. In the latter situation,
this has wider relevance than drugs targeting renal disease
and could be applied to phase I–II trials of promising
new drugs for any indication in which a specific concern may
exist around effects on renal haemodynamics or potential
nephrotoxicity.
STRATEGIC RECOMMENDATIONS FOR
FUTURE CLINICAL TRIALS INVOLVING
RENAL MRI
Following the roadmap for imaging biomarkers in oncology,
before a renal MRI biomarker can be widely used in clinical
research or routine practice it must cross two ‘translational
gaps’ [59]. First, the novel biomarker must be shown to be a
valid tool for testing hypotheses in a research setting and sec-
ond, it must be clinically useful and cost effective in the rou-
tine management of patients. In this section we will focus
largely on the former, though there is some overlap. Note
that a valid biomarker does not necessarily play an essential
role in the pathway to target organ injury, for example,
haemoglobinA1c is not pathogenic but is a good biomarker of
diabetic control and predictive of clinical outcomes [60]. We
adhere to the general principles described previously in the
roadmap for translation of imaging biomarkers in cancer
[59], but propose additional recommendations specific to the
future study of multiparametric renal MRI biomarkers with
the aim of increasing the speed of their translation.
Recommendations are summarized in Figure 1.
Recommendation 1: Funding applications, publications
and published protocols describing renal MRI
biomarkers should report full details of study design,
patient selection, image acquisition, post-processing,
image analysis and quality assurance processes [59]
Useful information is available from the FDA’s draft guid-
ance on Clinical Trial Imaging Endpoint Process Standards
[61]. To facilitate the comparison between protocols, the
PARENCHIMA consensus-building initiatives will include the
development of a standardized checklist or template onto which
FIGURE 1: Summary of recommendations to progress renal MRI biomarkers. Technical validation should precede biological and clinical vali-
dation, although this process is likely to occur in parallel as well as sequentially; this bidirectional process is represented by the arrows. The
labels with the preﬁx ‘R’ indicate the speciﬁc recommendation linked to each statement.
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studies can map specifics of study design, patient selection, im-
age acquisition, post-processing, image analysis and quality as-
surance processes. Harmonization of these fields with existing
standards such as Digital Imaging and Communications in
Medicine (DICOM) should also be considered to facilitate in-
terfacing with existing imaging data management systems.
Recommendation 2: Technical validation should be
achieved prior to multisite clinical studies in order to
de-risk costly and time-consuming studies and to in-
form statistical analysis of the results [59]
Technical validation includes determining the accuracy,
precision and repeatability of measurements, as well as cross-
site and cross-vendor reproducibility. Technical validation
can be approached in a study-specific manner, with the meth-
ods and protocols applied in the study tested prior to patient
recruitment. This approach was followed by the Consortium
for Radiologic Imaging Studies of Polycystic Kidney Disease
(CRISP) study in ADPKD [16] and is suitable for studies us-
ing biomarkers or assays that have not yet been technically
validated. As demonstrated in the landmark CRISP study,
these methods have the potential to become reference stand-
ards for future studies and clinical translation, as well as a
benchmark against which to evaluate future methods. Risks
with study-specific technical validation are duplication of
efforts and potential emergence of competing standards.
Research coordination efforts combining technical validation
with a strategy to upscale the validated methods and increase
their availability are critical to avoiding these potential prob-
lems and in providing a sustainable solution. Researchers
should adhere to standardized terminology and analysis
approaches for quantitative imaging biomarkers as previously
described [62, 63].
Recommendation 3: For multicentre studies, a core
panel of MRI biomarkers should be defined that are
standardized, comparable and deliverable at all sites
The term ‘multiparametric MRI’ refers to any combination
of functional MRI measures alongside standard anatomical
images. In the context of renal imaging, there are a range of
functional MRI measures that differ in their complexity and
availability. At present, candidates for this panel are likely to in-
clude TKV, renal artery blood flow, longitudinal relaxation
time (T1), transverse relaxation time (T2) and the apparent dif-
fusion coefficient (ADC). However, a core panel should not be
a barrier that limits current expertise and future refinement of
more advanced techniques, for example, for cortical perfusion
or tissue stiffness. In some cases, substudies could allow efficient
evaluation of novel biomarkers if these are ‘added on’ to the
core panel of biomarkers in those centres with the necessary ex-
pertise. Statistical input to ensure appropriate study design and
power of such substudies would be essential, and with future
technological advances the core panel of biomarkers is likely to
expand.
Recommendation 4: Studies using multiparametric MRI
should explicitly describe their approach to the
integrated analysis of multiple measures, and data that
may inform future prioritization of biomarkers should
be reported in full
Integration of multiple MRI biomarkers is potentially com-
plex, with each measurement generating large amounts of data
that can be analysed on a whole-kidney basis or by segmenta-
tion (e.g. cortex, medulla and corticomedullary difference). The
degree of variation across the kidney may also be important.
Due to the range of pathological processes involved in CKD
progression, it is likely that multiple measures are required to
differentiate between phenotypic groups. While some measures
may be additive in combination, others may be redundant. This
may differ depending on the clinical situation. Establishing ref-
erence values for MRI biomarkers will be important and com-
plex MRI datasets (especially if multiparametric) will require
detailed analysis plans with input from both imaging and bio-
statistics experts.
Recommendation 5: The biological validity of renal MRI
needs to be determined through cross-sectional studies
in which MRI biomarkers are compared against renal
biopsy
In clearly defined patient cohorts (both CKD and renal
transplantation), individual or combinations of MRI bio-
markers should be compared against quantitative renal histol-
ogy techniques that measure important biological processes
such as fibrosis (glomerulosclerosis score, extent of interstitial
fibrosis, collagen accumulation), inflammation (density of in-
flammatory cells and cell subtypes), peritubular capillary den-
sity and podocyte loss. Such studies will be greatly aided by the
use of digital pathology techniques and computer-driven meth-
ods for quantification [64]. In addition, combining MRI and re-
nal biopsies for the determination of cortical volume and
glomerular density offers the potential to provide estimates of
glomerular numbers and single nephron GFR.
Recommendation 6: To overcome the limitations of
biopsy, biological validation also requires studies
assessing MRI biomarkers in animal models of renal
disease or in human nephrectomy specimens, as well as
in silico studies linking biology to measurement
There are potential weaknesses of relying only on a routine
renal biopsy as the reference standard against which to evaluate
MRI measures. These include the tiny sample volume of renal
biopsy compared with the whole-kidney coverage of MRI data,
the ‘patchy’ nature of kidney damage that may not be reflected
in a small biopsy sample, that patients undergoing renal biopsy
for clinical reasons are not necessarily representative of the full
spectrum of CKD and that renal biopsy does not always allow
validation of medullary biomarkers. To date, whole-kidney
MRI results have been compared with biopsy without matching
to the sampled site, resulting unsurprisingly in only modest cor-
relations between whole-kidney MRI measures and quantifica-
tion of fibrosis on biopsy [9].
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Validation studies in animal models or nephrectomy
specimens can bridge these gaps. Preclinical models may allow
comprehensive and detailed validation of biomarkers against
well-characterized pathological states and the effect of interven-
tions. However, even these studies are limited because many
biological properties change at the same time during disease
progression. Hence observing a correlation between, for
instance, cortical relaxation time and a histopathological mea-
sure of fibrosis does not necessarily demonstrate a causal rela-
tion between the two if specific interventions are not used.
Therefore it is important that experimental work is further
complemented by thorough in silico modelling trying to pro-
vide a direct mechanistic link between biological properties and
MRI biomarkers and generating testable hypotheses.
Recommendation 7: MRI biomarkers should be tested
prospectively in longitudinal patient cohort studies with
adequate sample size and suitable length of follow-up
Demonstrating a close and biologically plausible association
between renal MRI biomarkers and clinically important out-
come measures is vital and is the criterion used by regulatory
bodies to assess biomarkers and surrogate endpoints. A recent
study of BOLD MRI by Pruijm et al. [51] is a rare example of a
study addressing these questions directly. Within this broad
concept, there are several points to consider. While demonstra-
tion of biological and clinical validity is separate, there are prac-
tical and efficiency reasons to link their study, so we
recommend that well-characterized participants in cross-
sectional studies are also recruited for longitudinal follow-up
with assessment of clinical outcomes, with or without repeat
MRI scanning. Serial imaging should establish which MRI
parameters change over time in association with or predating
CKD progression or regression. These studies would also be im-
portant to establish the optimal frequency of serial renal imag-
ing. A further requirement for biological and clinical validity is
demonstrating that MRI biomarkers change in response to
treatment.
Recommendation 8: Studies should be performed that
assess MRI biomarkers against hard clinical endpoints
of CKD progression
Hard clinical endpoints such as the development of ESKD
(eGFR<15mL/min/1.73m2 or initiation of RRT) or substantial
reductions in GFR of 30, 40 or>50% (doubling of serum creati-
nine) are the only measures of CKD progression currently ac-
cepted by the FDA. MRI biomarkers should be evaluated in
terms of their ability to identify patients at higher risk of pro-
gressing to these endpoints. Alternative definitions of CKD pro-
gression (e.g. percentage reductions in eGFR, eGFR trajectory)
should be recorded as secondary endpoints. This approach has
the obvious drawback of requiring larger numbers of partici-
pants and longer study duration, which will be more challeng-
ing in terms of feasibility and cost. Evaluation of MRI
biomarkers in populations defined as high risk of progression
based on clinical features may permit more feasible sample sizes
and shorter study length. Alternatively, efficient methods of
tracking long-term outcomes may be utilized, for example,
through the use of registry data for long-term tracking of RRT
initiation data.
Recommendation 9: In both cross-sectional and longitu-
dinal studies, careful consideration must be given to the
choice of method for assessing renal function
Assessing GFR is a critical element to any clinical study of
CKD, although it should be noted that cross-sectional compari-
sons against GFR alone will not be adequate to establish the
utility of MRI biomarkers. The gold standard method for GFR
measurement is inulin clearance, but this is invasive and expen-
sive and inulin is difficult to dissolve and maintain in solution.
Measurement of GFR using other exogenous filtration markers
(e.g. iohexol) is the reference method in clinical research and
some clinical scenarios and would be optimal for cross-sectional
studies [65]. eGFR is easier to obtain and theoretically could be
more suitable for longitudinal studies tracking changes in renal
function over time. However, eGFR lacks precision, especially
at higher GFR levels, and is not only dependent on GFR, but
also on non-GFR determinants included in the equation [65],
although in longitudinal studies non-GFR determinants of se-
rum creatinine may become less relevant since they will not
vary considerably in the same individual. The accuracy of eGFR
can be improved by using combined creatinine and cystatin-
based estimating equations, but the benefit is marginal [66].
Given the weight of evidence that albuminuria is a marker of
kidney damage and an independent predictor of adverse out-
comes associated with CKD [67], studies should correlate MRI
measures with the magnitude of albuminuria and changes in al-
buminuria over time. In cross-sectional studies, fasting and hy-
dration should be documented, as these are known to modulate
MRI biomarkers and estimates of renal function.
Recommendation 10: Biosample storage, data storage
and matched image banking should be built into
prospective MRI studies to generate linked clinical data,
biosamples and imaging biomarkers
Imaging biobanks will permit assessments of combinations
of genetic, molecular and imaging biomarkers, the use of addi-
tional filtration markers that may help improve the accuracy of
eGFR equations or the use of a panel of urine and blood injury
markers to provide an additional way of establishing biological
validity (e.g. neutrophil gelatinase-associated lipocalin, kidney
injury molecule-1) [68]. A similar strategy holds for biomarkers
of renal fibrosis (e.g. matrix metalloproteinase 9 and bone mor-
phogenic protein 7), inflammation biomarkers (e.g. monocyte
chemoattractant protein 1, tumour necrosis factor receptor 1
and 2) [69] or combined proteomic panels (e.g. CKD 273) [70].
Recommendation 11: Careful consideration of aetiology
of CKD should be incorporated into the study design
It may be challenging to strike a balance between a more
generalizable CKD population that is heterogeneous in terms of
the clinical and pathophysiological characteristics versus a
tightly defined patient cohort with greater homogeneity but
from which findings may not be generalizable and who may be
more difficult to recruit. Studies focused on specific disease
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aetiologies may be important to identify MRI measures that are
relevant to a particular disease. The importance of renal size
and cyst volume in polycystic kidney disease is one example of
this [71]. Where study design includes one or more disease-
specific subgroup analyses, it is important to ensure that each
subgroup analysis is adequately powered to detect the proposed
outcomes. In addition, care should be taken in assigning aetiol-
ogy and if this is unclear, it should be recognized as such to limit
uncertainty introduced by misdiagnosis. The presence of
comorbidities and their potential effect on MRI biomarkers
should also be considered.
Recommendation 12: Data and original images should
be made available for secondary research and/or
educational or commercial purposes when appropriate
Collecting patient data, especially MR images, is extremely
costly. Sharing these data makes the most of public research
funding, in some cases reducing the need for rescanning
patients, and promotes scientific rigour by enabling indepen-
dent verification of study results. For MRI methods research,
the availability of large well-organized image banks has major
value as a benchmark for new methods, and the use of common
reference data can also be a significant driver for more stan-
dardized approaches. In order to enable efficient data sharing,
studies should establish detailed a priori data management
plans and conform to good data management practice, the use
of standards such as DICOM to improve interoperability and
dedicated software designed for managing and sharing medical
images in a multicentre setting. Patient consent forms should
account for broad future data sharing where appropriate.
Recommendation 13: Health economic evaluations must
be factored into clinical research studies where possible
Measurement of MRI biomarker panels is expensive com-
pared with blood and urine biomarkers. Consequently, finan-
cial concerns may prevent the uptake of MRI biomarkers,
even when clinically validated. Robust health economic stud-
ies will form an important element of future research to de-
termine whether the higher initial cost is offset by savings in
health care–related costs from improved patient treatment
pathways or outcomes that are enabled by the imaging
biomarker(s).
Recommendation 14: Regulatory requirements and the
needs of industry and small and medium-sized
enterprises should be considered when designing studies
aimed at the validation of renal MRI biomarkers
Obtaining regulatory approval is a lengthy process, espe-
cially in slowly progressive chronic diseases such as CKD.
This was seen in the 12-year process of qualification of TKV
in ADPKD. Hence it is critical to engage with this process
early and ensure that data are collected according to the ap-
propriate standards. In addition, the requirements of the
pharmaceutical industry for drug development should be
considered. Collaboration with MRI scanner manufacturers
will be essential to support the scalability of the validated im-
aging biomarkers, which can ultimately be achieved only if
vendors agree to distribute them on their platforms; this pro-
cess should also lead to reductions in scan acquisition times
for multiparametric protocols. Small and medium-sized
enterprises will likely play an important role in the scalability
of the biomarkers by providing software and services for cen-
tralized or local image processing and quality control.
Involving them early in the setup and running of studies will
ensure that imaging biomarkers are collected in a manner
that is compatible with real-world conditions, shortening the
route to clinical translation.
SUMMARY
Renal MRI has enormous potential to allow assessment of path-
ophysiological changes in the kidney that may improve diagno-
sis and prognosis and guide treatment in patients with kidney
disease. By issuing this position paper, we hope to support and
align the growth of a body of complementary technical, preclin-
ical and clinical research and provide a structure by which mul-
ticentre studies in this field can be accelerated, with the ultimate
aim of improving clinical outcomes in patients with CKD.
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